3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
9
Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma, Mantle-Cell
7
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, B-Cell
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Leukemia
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Fallopian Tube Neoplasms
1
Burkitt Lymphoma
1
Interventions
Gemcitabine
3
Cyclophosphamide
3
romidepsin
2
pembrolizumab
2
duvelisib
2
Vincristine
2
Prednisone
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Biopsy
2
Azacitidine
2
tazemetostat
1
spartalizumab
1
somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)-
1
sodium-iodide symporter
1
sintilimab
1
ruxolitinib
1
ixazomib
1
ivarmacitinib
1
fludarabine
1
etoposide phosphate
1
cemiplimab
1
cabiralizumab
1
belinostat
1
X-Rays
1
Watchful Waiting
1
Tomography, X-Ray Computed
1
Specimen Handling
1
Prednisolone
1
Photons
1
Oxaliplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Peripheral
×
Bendamustine Hydrochloride
×
90 days
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled